Nodal marginal zone B-cell lymphoma
MONDO:0019465Nodal marginal zone B-cell lymphoma is a rare, indolent B-cell non-Hodgkin lymphoma, characterized by abnormal clonal proliferation of mature B-lymphocytes with involvement of the lymph nodes, sometimes the bone marrow, and rarely the blood. Clinically it presents with disseminated peripheral, abdominal and/or thoracic lymphadenopathy. Cytopenia and bulky tumors (greater than 5 cm) are rare. Association with Hepatitis C virus and chronic inflammation has been reported.
Also known as: Monocytoid B-cell lymphoma, NMZL, nodal marginal zone B-cell lymph., nodal marginal zone B-cell lymphoma, nodal marginal zone lymphoma
2015 clinical trials for this condition and its sub-types, 16 tagged with Nodal marginal zone B-cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Immunotherapy combo shows promise for Tough-to-Treat blood cancers
Disease control CompletedThis phase 2 trial tested the immunotherapy drug pembrolizumab (Keytruda) alone or combined with idelalisib or ibrutinib in 65 patients with chronic lymphocytic leukemia (CLL) or low-grade B-cell non-Hodgkin lymphoma (NHL) that had returned or stopped responding to treatment. The…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New combo shows promise for tough lymphomas
Disease control CompletedThis study tested adding lenalidomide to a standard chemotherapy regimen (EPOCH-R) in 55 people with aggressive B-cell lymphomas linked to the MYC gene. The goal was to find the best dose and see if the combination improves how long patients live without their cancer getting wors…
Phase 1/2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC